PMID- 21438794
OWN - NLM
STAT- MEDLINE
DCOM- 20110915
LR  - 20151119
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 27
IP  - 6
DP  - 2011 Jun
TI  - Remission of major depressive disorder without adverse events: a comparison of 
      escitalopram versus serotonin norepinephrine reuptake inhibitors.
PG  - 1089-96
LID - 10.1185/03007995.2011.567255 [doi]
AB  - OBJECTIVE: An antidepressant's tolerability, generally captured as the frequency 
      and severity of adverse events (AEs), is often as important as its efficacy in 
      determining treatment success. This study used a composite outcome - remission of 
      major depressive disorder (MDD) without AEs - to compare the benefit-risk 
      profiles of escitalopram versus the norepinephrine reuptake inhibitors (SNRIs) 
      duloxetine and venlafaxine extended release (XR). METHODS: Pooled data from three 
      randomized, double-blind, multicenter trials were analyzed, in which patients 
      with MDD were treated for 8 weeks with either escitalopram (n = 462) or an SNRI 
      (n = 467). CLINICAL TRIAL REGISTRATION: clinicaltrials.gov identifiers: 
      NCT00108979; NCT00384436. MAIN OUTCOME MEASURES: The composite outcome was 
      defined as remission (Montgomery-Asberg Depression Rating Scale [MADRS] score 
      </=10) and concurrent absence of an AE. The proportions of remitted patients free 
      of (1) any AEs, (2) moderate-to-severe AEs, and (3) study drug-related AEs were 
      compared between treatment groups at each study visit and longitudinally across 
      study visits common to all trials during the first 8 weeks of treatment. RESULTS: 
      At endpoint (week 8), escitalopram-treated patients were more likely than 
      SNRI-treated patients to experience remission free of any AEs (28.4 vs. 21.6%; 
      p = 0.0179) and remission free of study drug-related AEs (45.2 vs. 36.8%; 
      p = 0.0092). Compared to SNRI-treated patients, escitalopram-treated patients had 
      38% greater odds of remission free of any AEs, 28% greater odds of remission free 
      of moderate-to-severe AEs, and 34% greater odds of remission free of study 
      drug-related AEs (all p < 0.05). CONCLUSION: Treatment of adult MDD patients with 
      escitalopram was significantly more likely to result in remission without 
      concurrent AEs compared to treatment with current SNRIs. Study limitations 
      include focus on only the initial 8 weeks of treatment and exclusion of trials 
      for which individual patient data were not obtained.
FAU - Signorovitch, James
AU  - Signorovitch J
AD  - Analysis Group, Inc., Boston, MA, USA. jsignorovitch@analysisgroup.com
FAU - Ramakrishnan, Karthik
AU  - Ramakrishnan K
FAU - Ben-Hamadi, Rym
AU  - Ben-Hamadi R
FAU - Yu, Andrew P
AU  - Yu AP
FAU - Wu, Eric Q
AU  - Wu EQ
FAU - Dworak, Heather
AU  - Dworak H
FAU - Erder, M Haim
AU  - Erder MH
LA  - eng
SI  - ClinicalTrials.gov/NCT00108979
SI  - ClinicalTrials.gov/NCT00384436
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110328
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Cyclohexanols)
RN  - 0 (Neurotransmitter Uptake Inhibitors)
RN  - 0 (Thiophenes)
RN  - 0DHU5B8D6V (Citalopram)
RN  - 333DO1RDJY (Serotonin)
RN  - 7D7RX5A8MO (Venlafaxine Hydrochloride)
RN  - 9044SC542W (Duloxetine Hydrochloride)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
EIN - Curr Med Res Opin. 2011 Sep;27(9):1708
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Citalopram/*therapeutic use
MH  - Cyclohexanols/*therapeutic use
MH  - Depressive Disorder, Major/*drug therapy
MH  - Double-Blind Method
MH  - Duloxetine Hydrochloride
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neurotransmitter Uptake Inhibitors/*therapeutic use
MH  - Norepinephrine/*metabolism
MH  - Remission Induction
MH  - Serotonin/*metabolism
MH  - Thiophenes/*therapeutic use
MH  - Treatment Outcome
MH  - Venlafaxine Hydrochloride
MH  - Young Adult
EDAT- 2011/03/29 06:00
MHDA- 2011/09/16 06:00
CRDT- 2011/03/29 06:00
PHST- 2011/03/29 06:00 [entrez]
PHST- 2011/03/29 06:00 [pubmed]
PHST- 2011/09/16 06:00 [medline]
AID - 10.1185/03007995.2011.567255 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2011 Jun;27(6):1089-96. doi: 10.1185/03007995.2011.567255. 
      Epub 2011 Mar 28.